X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1094) 1094
Publication (136) 136
Book Review (21) 21
Book Chapter (4) 4
Conference Proceeding (2) 2
Magazine Article (1) 1
Paper (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (778) 778
farnesyltranstransferase (619) 619
alkyl and aryl transferases - antagonists & inhibitors (560) 560
enzyme inhibitors - pharmacology (542) 542
animals (518) 518
farnesyltranstransferase - antagonists & inhibitors (463) 463
oncology (287) 287
mice (255) 255
index medicus (247) 247
antineoplastic agents - pharmacology (214) 214
enzyme inhibitors - therapeutic use (184) 184
biochemistry & molecular biology (179) 179
chemistry, medicinal (170) 170
ras (166) 166
antineoplastic agents - therapeutic use (165) 165
female (163) 163
farnesyltransferase inhibitors (159) 159
cancer (153) 153
enzyme inhibitors - chemistry (153) 153
farnesyltranstransferase - metabolism (150) 150
male (140) 140
structure-activity relationship (127) 127
farnesyl-protein transferase (125) 125
pharmacology & pharmacy (123) 123
farnesyltransferase (119) 119
apoptosis - drug effects (117) 117
cell line, tumor (114) 114
rats (113) 113
neoplasms - drug therapy (112) 112
apoptosis (108) 108
ras proteins - metabolism (108) 108
tumor cells, cultured (104) 104
farnesyltransferase inhibitor (102) 102
signal transduction (100) 100
chemistry, organic (99) 99
enzyme inhibitors - chemical synthesis (99) 99
cells (97) 97
methionine - analogs & derivatives (95) 95
protein prenylation (95) 95
prenylation (93) 93
clinical trials as topic (92) 92
cell biology (91) 91
cell division - drug effects (91) 91
hematology (91) 91
protein prenylation - drug effects (91) 91
dose-response relationship, drug (90) 90
alkyl and aryl transferases - metabolism (89) 89
growth (89) 89
methionine - pharmacology (84) 84
molecular structure (84) 84
quinolones - pharmacology (84) 84
models, molecular (83) 83
signal transduction - drug effects (83) 83
alkyl and aryl transferases (82) 82
farnesyl transferase inhibitor (81) 81
in-vitro (80) 80
drug design (78) 78
research (78) 78
farnesyl transferase inhibitors (77) 77
middle aged (77) 77
transferases - antagonists & inhibitors (77) 77
aged (76) 76
mutation (76) 76
genes, ras (74) 74
imidazoles - pharmacology (71) 71
proteins (71) 71
treatment outcome (71) 71
quinolones - therapeutic use (69) 69
transgenic mice (69) 69
n-ras (68) 68
adult (67) 67
protein transferase (67) 67
cells, cultured (65) 65
expression (65) 65
pyridines - pharmacology (64) 64
article (62) 62
r115777 (60) 60
cell line (59) 59
k-ras (59) 59
phase-i (58) 58
antineoplastic agents - chemistry (57) 57
protein (57) 57
protein farnesyltransferase (57) 57
activation (55) 55
piperidines - pharmacology (55) 55
farnesylation (54) 54
mice, nude (54) 54
cell proliferation - drug effects (51) 51
antitumor-activity (50) 50
in-vivo (50) 50
analysis (46) 46
farnesyl (45) 45
antineoplastic combined chemotherapy protocols - therapeutic use (43) 43
oligopeptides - pharmacology (43) 43
phosphorylation (43) 43
blotting, western (42) 42
ras proteins - genetics (42) 42
time factors (42) 42
binding sites (39) 39
cell cycle - drug effects (39) 39
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1056) 1056
French (14) 14
Japanese (12) 12
Chinese (4) 4
German (2) 2
Italian (2) 2
Spanish (2) 2
Dutch (1) 1
Polish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


CA: A Cancer Journal for Clinicians, ISSN 0007-9235, 07/2010, Volume 60, Issue 4, pp. 222 - 243
Angiogenesis has become an attractive target for drug therapy because of its key role in tumor growth. An extensive array of compounds is currently in... 
CELL LUNG-CANCER | TYROSINE KINASE INHIBITORS | PHASE-III TRIAL | FARNESYL-PROTEIN TRANSFERASE | HYPOXIA-INDUCIBLE FACTOR | SUPPRESSES TUMOR-GROWTH | ONCOLOGY | ENDOTHELIAL-GROWTH-FACTOR | FACTOR EXPRESSION | VASCULAR-PERMEABILITY FACTOR | METASTATIC COLORECTAL-CANCER | Neoplasms - metabolism | Nucleic Acid Synthesis Inhibitors - pharmacology | Humans | Receptor Protein-Tyrosine Kinases - physiology | Antibodies, Monoclonal - therapeutic use | Receptors, Notch - antagonists & inhibitors | Protein Binding - drug effects | Angiogenesis Inhibitors - therapeutic use | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Neovascularization, Pathologic - prevention & control | Farnesyltranstransferase - antagonists & inhibitors | Thioredoxins - antagonists & inhibitors | Nucleic Acid Synthesis Inhibitors - therapeutic use | Basic Helix-Loop-Helix Transcription Factors - physiology | Antibodies, Monoclonal - pharmacology | Intracellular Signaling Peptides and Proteins - antagonists & inhibitors | Angiogenesis Inhibitors - pharmacology | Receptors, Notch - physiology | Neoplasms - blood supply | Basic Helix-Loop-Helix Transcription Factors - antagonists & inhibitors | Neoplasms - drug therapy | Signal Transduction - drug effects | Cell Transformation, Neoplastic | HSP90 Heat-Shock Proteins - antagonists & inhibitors | Intracellular Signaling Peptides and Proteins - physiology | Complications and side effects | Care and treatment | Ligands (Biochemistry) | Physiological aspects | Development and progression | Dosage and administration | Angiogenesis inhibitors | Neovascularization | Identification and classification | Growth factors | Cancer | Angiogenesis | Pharmacology | FDA approval | Drug therapy | Kinases | Tumors | hypoxia inducible factor (HIF) | kinase inhibitors | growth factors | angiogenesis inhibitors | VEGF | anti-angiogenesis
Journal Article
The Journal of Clinical Endocrinology & Metabolism, ISSN 0021-972X, 04/2011, Volume 96, Issue 4, pp. 997 - 1005
Inhibiting the Ras/Raf/MEK/ERK and RET kinase pathways with sorafenib and tipifarnib is well tolerated and active against thyroid cancer. Purpose: Ras/Raf/MAPK... 
BREAST-CANCER | PHASE-II TRIAL | ACTIVATION | R115777 | FARNESYLATION | DOXORUBICIN | ENDOCRINOLOGY & METABOLISM | MYELODYSPLASTIC SYNDROME | CARCINOMA | TUMORS | CHEMOTHERAPY | Niacinamide - analogs & derivatives | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | raf Kinases - antagonists & inhibitors | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Extracellular Signal-Regulated MAP Kinases - antagonists & inhibitors | Male | Phenylurea Compounds | Quinolones - pharmacology | Benzenesulfonates - administration & dosage | Protein Kinase Inhibitors - adverse effects | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Benzenesulfonates - adverse effects | Dose-Response Relationship, Drug | Benzenesulfonates - pharmacology | Oncogene Protein p21(ras) - antagonists & inhibitors | Pyridines - adverse effects | Quinolones - adverse effects | Aged, 80 and over | Adult | Female | Farnesyltranstransferase - antagonists & inhibitors | MAP Kinase Kinase Kinases - antagonists & inhibitors | Proto-Oncogene Proteins c-ret - antagonists & inhibitors | Pyridines - administration & dosage | Protein Kinase Inhibitors - administration & dosage | Quinolones - administration & dosage | Adenocarcinoma, Follicular | Carcinoma, Neuroendocrine | Signal Transduction - drug effects | Thyroid Neoplasms - drug therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Cell Differentiation - drug effects | Aged | Protein Kinase Inhibitors - pharmacology | Pyridines - pharmacology | Thyroid Neoplasms - pathology | Endocrine Care
Journal Article
Pharmacology and Therapeutics, ISSN 0163-7258, 07/2014, Volume 143, Issue 1, pp. 87 - 110
The cholesterol biosynthesis pathway, also known as the mevalonate (MVA) pathway, is an essential cellular pathway that is involved in diverse cell functions.... 
Farnesyl transferase inhibitors | Rho GTPase | Statins | Fibrosis | Geranylgeranyl transferase inhibitors | Asthma | C-REACTIVE PROTEIN | SMALL GTPASE RHOA | BRONCHIAL EPITHELIAL-CELLS | COENZYME-A REDUCTASE | GERANYLGERANYLTRANSFERASE-I INHIBITOR | HMG-COA REDUCTASE | RHO-KINASE INHIBITOR | RANDOMIZED CONTROLLED-TRIAL | PHARMACOLOGY & PHARMACY | SMOOTH-MUSCLE-CELLS | NF-KAPPA-B | rho-Associated Kinases - physiology | rho GTP-Binding Proteins - antagonists & inhibitors | Cardiovascular Diseases - drug therapy | Humans | Alkyl and Aryl Transferases - antagonists & inhibitors | Hydroxymethylglutaryl CoA Reductases - physiology | Lung Diseases - drug therapy | Mevalonic Acid - metabolism | rho GTP-Binding Proteins - physiology | rho-Associated Kinases - antagonists & inhibitors | Neoplasms - drug therapy | Animals | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Farnesyltranstransferase - antagonists & inhibitors | Pulmonary Disease, Chronic Obstructive - drug therapy | Enzymes | Hypercholesterolemia | Lung diseases | Physiological aspects | Cardiovascular diseases | Health aspects | Cancer | geranylgeranyl transferase inhibitors | farnesy transferase inhibtors | asthma | fibrosis | cancer | chronic obstructive pulmonary disease | Medical and Health Sciences | Medicin och hälsovetenskap
Journal Article
Journal of the American Chemical Society, ISSN 0002-7863, 04/2009, Volume 131, Issue 14, pp. 5153 - 5162
Journal Article
Biochemistry, ISSN 0006-2960, 08/2016, Volume 55, Issue 31, pp. 4366 - 4374
Some trans-prenyltransferases, such as long-chain C40 octaprenyl diphosphate synthase (OPPS), short-chain C15 farnesyl diphosphate synthase (FPPS), and C20... 
MECHANISM | UNDECAPRENYL PYROPHOSPHATE SYNTHASE | NITROGEN-CONTAINING BISPHOSPHONATES | CRYSTAL-STRUCTURE | BIOCHEMISTRY & MOLECULAR BIOLOGY | CHAIN ELONGATION | TIME | PROTON-TRANSFER | SUBSTRATE-ANALOG | Molecular Probe Techniques | Polyisoprenyl Phosphates - chemistry | Humans | Alkyl and Aryl Transferases - antagonists & inhibitors | Substrate Specificity | Geranyltranstransferase - antagonists & inhibitors | Dimethylallyltranstransferase - genetics | Alkyl and Aryl Transferases - genetics | Geranyltranstransferase - genetics | Enzyme Inhibitors - chemistry | Farnesyltranstransferase - antagonists & inhibitors | Dimethylallyltranstransferase - chemistry | Recombinant Proteins - metabolism | Alkyl and Aryl Transferases - chemistry | Fluorescent Dyes - chemistry | Mutagenesis, Site-Directed | Sesquiterpenes - chemistry | Saccharomyces cerevisiae Proteins - antagonists & inhibitors | Enzyme Inhibitors - pharmacology | Models, Molecular | Recombinant Proteins - chemistry | Imidazoles - pharmacology | Recombinant Proteins - genetics | Geranyltranstransferase - chemistry | Drug Discovery | Farnesyltranstransferase - chemistry | Molecular Probes - chemistry | Farnesyltranstransferase - genetics | Protein Conformation | Dimethylallyltranstransferase - antagonists & inhibitors | Kinetics | Diphosphonates - pharmacology | Amino Acid Substitution | Phosphates | Usage | Biochemistry | Chemical properties | Research | Chemical synthesis
Journal Article
Circulation Research, ISSN 0009-7330, 08/2004, Volume 95, Issue 4, pp. 380 - 388
Atheroma formation involves the movement of vascular smooth muscle cells (VSMC) into the subendothelial space. The aim of this study was to determine the... 
Akt | Diabetes | Statin | Atherosclerosis | ERK | atherosclerosis | OXIDATIVE STRESS | CARDIAC & CARDIOVASCULAR SYSTEMS | ACTIVATED PROTEIN-KINASE | PHOSPHATIDYLINOSITOL 3-KINASE | LOW-DENSITY-LIPOPROTEIN | PHOSPHOINOSITIDE 3-KINASE | INSULIN | statin | CELL-MIGRATION | EPIDERMAL-GROWTH-FACTOR | GENE-EXPRESSION | PERIPHERAL VASCULAR DISEASE | FOCAL ADHESION KINASE | HEMATOLOGY | diabetes | Lovastatin - pharmacology | Cells, Cultured - cytology | Humans | Mitogen-Activated Protein Kinase Kinases - physiology | Alkyl and Aryl Transferases - antagonists & inhibitors | Phosphatidylinositol 3-Kinases - antagonists & inhibitors | MAP Kinase Kinase 4 | Chromones - pharmacology | Myocytes, Smooth Muscle - drug effects | Muscle, Smooth, Vascular - drug effects | Cells, Cultured - drug effects | JNK Mitogen-Activated Protein Kinases - antagonists & inhibitors | Mitogen-Activated Protein Kinase 1 - physiology | p38 Mitogen-Activated Protein Kinases - physiology | Antibodies, Monoclonal - pharmacology | Mitogen-Activated Protein Kinase 1 - antagonists & inhibitors | Glucose - pharmacology | Imidazoles - pharmacology | Chemotaxis - drug effects | Farnesyltranstransferase | Anthracenes - pharmacology | Mitogen-Activated Protein Kinase 3 - physiology | Class I Phosphatidylinositol 3-Kinases | p38 Mitogen-Activated Protein Kinases - antagonists & inhibitors | JNK Mitogen-Activated Protein Kinases - physiology | Cells, Cultured - metabolism | TOR Serine-Threonine Kinases | Mitogen-Activated Protein Kinase 3 - antagonists & inhibitors | Chemotaxis - physiology | Sesquiterpenes | Flavonoids - pharmacology | Myocytes, Smooth Muscle - cytology | ras Proteins - physiology | Muscle, Smooth, Vascular - physiology | Isoenzymes - physiology | Protein-Serine-Threonine Kinases - physiology | Mitogen-Activated Protein Kinase Kinases - antagonists & inhibitors | Myocytes, Smooth Muscle - physiology | Morpholines - pharmacology | Sirolimus - pharmacology | Proto-Oncogene Proteins c-akt | MAP Kinase Signaling System - drug effects | Androstadienes - pharmacology | Protein Kinases - physiology | Proto-Oncogene Proteins - physiology | Phosphatidylinositol 3-Kinases - physiology | Polyisoprenyl Phosphates - pharmacology | Pyridines - pharmacology | Isoenzymes - antagonists & inhibitors
Journal Article
Proceedings of the National Academy of Sciences of the United States of America, ISSN 0027-8424, 6/2007, Volume 104, Issue 24, pp. 10022 - 10027
Bisphosphonate drugs (e.g., Fosamax and Zometa) are thought to act primarily by inhibiting farnesyl diphosphate synthase (FPPS), resulting in decreased... 
Enzymes | Yeasts | Electronic structure | Molecular structure | Terpenoids | Diphosphonates | Ligands | Biosynthesis | Diphosphates | Binding sites | Undecaprenyl diphosphate synthase | Geranylgeranyl diphosphate synthase | X-ray structure | Cell wall | FARNESYL DIPHOSPHATE SYNTHASE | POTENTIAL ROUTE | INHIBITION | MECHANISM | ISOPRENOID BIOSYNTHESIS | STRUCTURAL BASIS | NITROGEN-CONTAINING BISPHOSPHONATES | CRYSTAL-STRUCTURE | MULTIDISCIPLINARY SCIENCES | GERANYLGERANYL PYROPHOSPHATE SYNTHASE | DRUGS | Diphosphates - metabolism | Polyisoprenyl Phosphates - chemistry | Sesquiterpenes - metabolism | Models, Chemical | Stereoisomerism | Alkyl and Aryl Transferases - antagonists & inhibitors | Substrate Specificity | Crystallography, X-Ray | Isoenzymes - chemistry | Isoenzymes - metabolism | Transferases - metabolism | Farnesyltranstransferase - antagonists & inhibitors | Molecular Structure | Transferases - antagonists & inhibitors | Diterpenes - metabolism | Binding Sites | Dimerization | Diterpenes - chemistry | Alkyl and Aryl Transferases - chemistry | Sesquiterpenes - chemistry | Protein Structure, Secondary | Models, Molecular | Transferases - chemistry | Diphosphonates - metabolism | Polyisoprenyl Phosphates - metabolism | Farnesyltranstransferase - chemistry | Diphosphates - chemistry | Diphosphonates - chemistry | Hydrophobic and Hydrophilic Interactions | Saccharomyces cerevisiae - enzymology | Isoenzymes - antagonists & inhibitors | Usage | Research | X-ray spectroscopy | Plant cell walls | Guanosine triphosphatase | Biological Sciences | undecaprenyl diphosphate synthase | x-ray structure | geranylgeranyl diphosphate synthase | cell wall
Journal Article
Journal of Biological Chemistry, ISSN 0021-9258, 10/2007, Volume 282, Issue 42, pp. 30804 - 30816
Farnesyl-diphosphate synthase (FPPS) catalyzes the synthesis of farnesyl diphosphate, an important precursor of sterols, dolichols, ubiquinones, and prenylated... 
RAT-LIVER PEROXISOMES | ARABIDOPSIS-THALIANA | TRYPANOSOMA-CRUZI | PLASMODIUM-FALCIPARUM | BIOCHEMISTRY & MOLECULAR BIOLOGY | T-CELL-ACTIVATION | IN-VIVO | CHAIN-LENGTH DETERMINATION | PYROPHOSPHATE SYNTHASE | LEISHMANIA-DONOVANI | SACCHAROMYCES-CEREVISIAE | Protozoan Proteins - antagonists & inhibitors | Toxoplasmosis - enzymology | Sterols - biosynthesis | Baculoviridae | Geranyltranstransferase - genetics | Diphosphonates - therapeutic use | Farnesyltranstransferase - antagonists & inhibitors | Catalysis | Protein Prenylation - physiology | Amino Acid Sequence | Gene Expression | Recombinant Proteins - antagonists & inhibitors | Escherichia coli - enzymology | Isoenzymes - genetics | Enzyme Inhibitors - pharmacology | Bone Density Conservation Agents - therapeutic use | Enzyme Inhibitors - therapeutic use | Toxoplasmosis - diet therapy | Bone Density Conservation Agents - pharmacology | Alternative Splicing - drug effects | Escherichia coli - genetics | Farnesyltranstransferase - genetics | Toxoplasmosis - genetics | Gene Expression Regulation, Enzymologic - drug effects | Diphosphates - metabolism | Quantitative Trait Loci - physiology | Molecular Sequence Data | Gene Expression Regulation, Enzymologic - physiology | Protozoan Proteins - genetics | Toxoplasma - enzymology | Ubiquinone - biosynthesis | Geranyltranstransferase - antagonists & inhibitors | Farnesyltranstransferase - metabolism | Protozoan Proteins - metabolism | Isoenzymes - metabolism | Sesquiterpenes | Cloning, Molecular | Drug Design | Dolichol - biosynthesis | Diterpenes - metabolism | Geranyltranstransferase - metabolism | Recombinant Proteins - metabolism | Protein Prenylation - drug effects | Ubiquinone - analogs & derivatives | Alternative Splicing - physiology | Recombinant Proteins - genetics | Amino Acid Motifs | Animals | Toxoplasma - genetics | Polyisoprenyl Phosphates - biosynthesis | Diphosphonates - pharmacology | Isoenzymes - antagonists & inhibitors
Journal Article
Journal Article